Following its July 2024 meeting, the European Medicines Agency’s (EMA) safety committee (PRAC) has recommended new measures on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
The aim is to minimize the risk of aspiration and pneumonia aspiration reported in patients taking GLP-1 RAs who undergo surgery with general anesthesia or deep sedation. GLP-1 RAs are medicines used for treatment of type 2 diabetes and obesity.
Notable among such products are Novo Nordisk’s (NOV: N) semaglutide, marketed under the trade name Wegovy for obesity and Ozempic for diabetes, and Eli Lily’s tirzepatide, sold as Mounjaro and Zepbound.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze